Humana (HUM) Stock Forecast & Price Target

Humana is a top-performing private health insurer in the US with a strong focus on government-sponsored programs. They have a diverse range of healthcare services, including primary care and pharmacy benefit management. This, coupled with their positive financial outlook and solid execution framework, makes them a solid choice for long-term investment. However, investors should be wary of potential risks, such as government policy changes and fluctuations in margin inputs. The company's recent earnings demonstrate a strong performance, with better-than-expected cost trends and stable membership growth. In addition, their strong management team and capital allocation strategies contribute to our positive outlook, reflected in our price target of $269.

Humana is heavily reliant on government-sponsored programs for its medical membership, with an estimated 60% of its total revenue coming from Medicare, Medicaid, and military programs. The company is facing near-term risks, with low visibility on deferred care costs due to the COVID pandemic and potential legislative risk in budget reconciliation. There is also potential headwinds due to redetermination headwinds in Medicaid and Democratic efforts to expand exchanges. Despite its strong recent performance, Humana's future earnings outlook remains uncertain and its stock may be at risk if these factors negatively impact its financials.